PEIJIA MEDICAL SHONE AT TWO MAJOR STRUCTURAL HEART DISEASE CONGRESSES TO DEMONSTRATE INNOVATION-Brief News on Innovation-

You are about to leave Peijia Medical's official Chinese website.

You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.

Cancel

Continue

Company News Brief News on Innovation

PEIJIA MEDICAL SHONE AT TWO MAJOR STRUCTURAL HEART DISEASE CONGRESSES TO DEMONSTRATE INNOVATION

2024-04-22 10:59:32

On March 18-24 and April 15-20, 2024, Peijia Medical shone at the 5th China Structural Heart Disease Conference and CHINA VALVE (HANGZHOU) 2024 respectively, showcasing the Company's cutting-edge innovative technologies and product layout in the field of heart valve therapy. Through various forms of procedural demonstrations, academic discussions and training workshops, Peijia Medical participated in the conferences and discussed the latest advances in the field of structural heart disease with industry experts and scholars. The Company will continue to dedicate itself to promoting the progress of the industry and patients' health, contributing to a healthy China.

Prev：NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) SYSTEM APPROVED BY THE NMPA

Next：MonarQ™ Transcatheter Tricuspid Valve Replacement (TTVR) Innovative Device: The Latest Results of the FIM Clinical Implantation Were Presented at New York Valves 2024